路透香港9月11日 - 中国生物制药公司--劲方医药科技（上海）股份有限公司2595.HK：
* 全球发售7,760万股H股，发售价每股20.39港元；9月11日开始香港公开发售，9月19日开始于联交所买卖
* 公司成立于2017年，是一家生物制药公司，专注于肿瘤（涵盖多种实体瘤的不同治疗线）以及自体免疫和炎症性疾病领域的新治疗方案开发；核心产品GFH925（fulzerasib，商品名达伯特®）是一款我们自主发现的新药物，已在中国获商业化批准，其用于治疗晚期非小细胞肺癌
* 包括RTW基金、TruMed、OrbiMed、Vivo基金、汇添富以及富国基金在内的8名基石投资者同意认购总金额为1亿美元的股份
欲览详情，请点击此处
(Reporting By Alison Lui)
((alison.lui@thomsonreuters.com; +852 3462 7749;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.